What's in Oculis's pipeline?

Oculis has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Oculis's portfolio?

Top competitors by shared drug class: Bristol-Myers Squibb, ClinAmygate, F. Johannes Plate, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/oculis.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Oculis — Portfolio Competitive Intelligence Brief

Oculis pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
OCS-01	OCS-01	phase 3	anti-VEGF inhibitor	VEGF	Ophthalmology

Therapeutic area mix

Ophthalmology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bristol-Myers Squibb · 1 shared drug class
ClinAmygate · 1 shared drug class
F. Johannes Plate · 1 shared drug class
First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
First Affiliated Hospital of Zhejiang University · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Oculis:

Cite this brief

Drug Landscape (2026). Oculis — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oculis. Accessed 2026-05-14.